Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer.

Onco Targets Ther · 2014 · PMC4199819 · PMID 25336975

Europe PMC DOI

hedged sentence

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not reach statistical significanceP =0.19not close (p > 0.1)

Despite a trend of improved OS in the trebananib arm being shown (median 19.0 months vs 17.3 months in the control arm), the difference did not reach statistical significance (HR =0.86, P =0.19) at the interim analysis, and mature survival data are anticipated during 2014.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.